Genmab raises 2022 sales outlook to top USD 1.6bn

Biotech firm Genmab is once again counting on sales advancements, projecting a revenue of DKK 10.8–12bn (USD 1.6–1.8bn) in the current financial year.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
by ANDREAS LØNSTRUP, translated by daniel pedersen

Genmab ended 2021 with a revenue of DKK 8.5bn (USD 1.3bn), compared to DKK 10.1bn (USD 1.5bn) in 2020, and an operating profit (EBIT) of DKK 3bn (USD 461m) against DKK 6.3bn (USD 964m) the preceding year, when an extraordinary one-off payment of DKK 4.4bn (USD 672m) from partner Abbvie lifted profits.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading